Nachrichten zur Eli Lilly & Co. Aktie

Eli Lilly (LLY) Stock Sinks As Market Gains: Heres Why

In the most recent trading session, Eli Lilly (LLY) closed at $935.58, indicating a -1.98% shift from the previous trading…

Bank of America sees Eli Lilly’s Foundayo as preferred oral GLP-1

Eli Lilly and Co (NYSE:LLY) is entering the US market slightly ahead of schedule with its oral GLP-1 weight-loss therapy…

Zulassung von Lillys Adipositas-Pille eröffnet neue Front im Abnehmkrieg

Die Pille des Pharmariesen wird auf dem boomenden, milliardenschweren Markt für Adipositas-Medikamente gegen einen Rivalen von Novo Nordisk antreten. Der…

Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison

Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start…

Wall Street sees multi-billion dollar debut for Lillys obesity pill despite Novo lead

Eli Lillys newly approved weight-loss pill is expected to generate billions in sales as soon as this year, with analysts…

Novo VP Weighs In on Approval of Lilly’s Obesity Pill

Jamey Millar, executive vice president, US operations of Novo Nordisk, reacts to Eli Lilly’s once-daily weight-loss pill, called Foundayo, winning…

Novo’s New US Chief on Lilly’s Rival Weight-Loss Pill

Novo Nordisk Executive Vice President for US Operations Jamey Millar discusses the US approval of competitor Eli Lillys obesity pill,…

AKTIE IM FOKUS: Eli Lilly ziehen weiter an - Diätpille in den USA zugelassen

NEW YORK (dpa-AFX) - Nach der Zulassung der Diätpille von Eli Lilly in den USA…

Eli Lilly opposes push to pass Trumps drug pricing deals into law, CEO says

Eli Lilly opposes the White Houses push to codify "most favored nation" drug pricing into law, CEO Dave Ricks said…

Stocks making the biggest moves midday: Eli Lilly, Hasbro, Philip Morris, Intel, Micron & more

These are the stocks posting the largest moves in midday trading.…

FDA approves Eli Lillys GLP-1 pill, opening the next phase of the weight loss drug market

The FDA approval of Eli Lillys GLP-1 pill Foundayo comes nearly three months after Novo Nordisks oral version of Wegovy…

Lillys weight-loss pill wins US approval

The U.S. Food and Drug ?Administration on Wednesday approved Eli Lillys weight-loss pill, making it the second to market after…

Market movers: Nike, RH, Tiziana Life Sciences, Eli Lilly…

…

Eli Lilly weight loss pill Foundayo approved by FDA, shares rise

Eli Lilly and Co (NYSE:LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults…

Barclays reiterates Eli Lilly stock Overweight on acquisition

Barclays reiterates Eli Lilly stock Overweight on acquisition…

Heres Why Eli Lilly (LLY) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet

Eli Lilly said on Tuesday it would buy Centessa ?Pharmaceuticals ?in ?a deal valued at up to $7.8 billion.…

Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly

Longer subscriptions offer lower monthly pricing, with people expected to save up to $1,200 a year on the injection and…

Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US

Novo Nordisk will launch a discounted subscription plan for U.S. Wegovy patients paying for the drug themselves, offering monthly ?prices…

Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio

Eli Lilly and Co $LLY said on Tuesday it will acquire Centessa Pharmaceuticals $CNTA for $38 per share in cash,…

Eli Lillys CEO Says This Could Be a Game Changer for Its Business

The healthcare stock may not be running out of growth catalysts anytime soon.…

Eli Lilly: 2,75-Mrd.-USD-Deal sichert KI-Wirkstoffe der nächsten Generation!

Eli Lilly baut sein Portfolio im Bereich der KI-gestützten Wirkstoffforschung durch eine bis zu 2,75 Mrd. USD schwere Vereinbarung mit…

Eli Lilly teams up with Insilico to accelerate AI-powered drug development

Eli Lilly and Co (NYSE:LLY) has entered into a drug discovery collaboration with Insilico Medicine, a clinical-stage biotechnology firm focused…

Prediction: Buying Pfizer Stock Today Could Set You Up for Life

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldnt count the company out.…

Healthcare ETFs in Spotlight Amid Eli Lilys $2.8B AI Drug Move

Eli Lillys $2.75B AI drug deal with Insilico spotlights healthcare ETFs as investors seek diversified exposure to the fast-growing AI-driven…

Eli Lilly expands AI drug push with multibillion-dollar Insilico deal

…

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market

U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered drugs to the…

1 Reason Eli Lilly Stock Is Still a Buy

Eli Lilly is much more than just a weight loss stock.…

Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?

Its not much of a contest right now.…

Could Buying Eli Lilly Today Set You Up for Life?

Eli Lilly is leading the GLP-1 market, and investors are enthralled with the stock.…

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

The latest trading day saw Eli Lilly (LLY) settling at $916.31, representing a +1.47% change from its previous close.…

Want to Buy the Dip on Eli Lilly? Consider This Low-Cost Vanguard ETF

After nearly tripling between 2023 and the end of 2025, Lilly is undergoing a steep sell-off in 2026.…

Top Analyst Reports for Eli Lilly, RTX & Abbott

Eli Lilly leads top analyst picks as GLP-1 demand, pipeline advances, and global growth momentum drive strong outlook despite rising…

U.S. executives, from Apple to Eli Lilly, revamp their push into the worlds second-largest economy at the China Development Forum

More than 80 global executives traveled to Beijing this weekend for the state-organized China Development Forum.…

Heres How Much Upside Eli Lilly Stock Has, According to Analysts

Eli Lillys stock has been receiving many upgrades after posting strong quarterly results in February.…

Can Hims & Hers (HIMS) Turn Novo Nordisk Truce And New CCO Hire Into Lasting Brand Advantage?

Earlier in March 2026, Hims & Hers Health announced that Kathryn Beiser, a veteran of Discover, Kaiser Permanente, Eli Lilly,…

Should You Buy Eli Lilly Stock Before April 10?

A catalyst for stock performance may be just ahead.…

Beijing courts Eli Lilly as weight-loss drug race drives $3bn China commitment

Beijing courts Eli Lilly as weight-loss drug race drives $3bn China commitment…

LLYs Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D

Eli Lilly reports strong Phase III results for retatrutide in type 2 diabetes, with significant A1C reduction and up to…

Why Eli Lilly Remains My Top Obesity Bet

…

Lilly GLP-1 drug rivals Novos pipeline treatment on gut side effects but throws up skin concern

New trial data complicates the competitive picture in the fast-growing obesity drug market Eli Lilly and Cos (NYSE:LLY) experimental weight-loss…

OTC Markets Hosts Virtual Investor Presentation with H.H. Kim, CEO and President of MetaVia, and David Bautz, PhD, Senior Analyst at Zacks SCR

NASDAQ: MTVALili Elston: Hello, and welcome to the Life Sciences Investor Forum. On behalf of OTC Markets and our co-host,…

Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals

Both have plenty to offer investors, but one has a better outlook.…

Eli Lillys new shot shows solid weight loss in study — plus, a way for Nvidia to perk up

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.…

Is It Too Late to Buy Eli Lilly?

Eli Lillys GLP-1 drugs are leaders in a new and exciting drug category, but investors already know this fact.…

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound…

Eli Lilly’s next-generation obesity drug delivers strong results in late-stage trial

Eli Lilly and Co (NYSE:LLY) has reported positive results from its late-stage trial of retatrutide, a next-generation obesity drug, demonstrating...…

Roche Vs. Eli Lilly: Nvidia Deals, Obesity Battles Stoke Rivalry (Id Buy Both)

…

Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics

Each of these companies could benefit from this high-growth market over time.…

HSBC drops blunt verdict on 150-year-old dividend stock

Eli Lilly has spent the last decade transforming from a reliable but unremarkable dividend payer into one of the most…